<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mes</journal-id><journal-title-group><journal-title xml:lang="ru">Экстремальная биомедицина</journal-title><trans-title-group xml:lang="en"><trans-title>Extreme Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3033-8964</issn><issn pub-type="epub">3033-8972</issn><publisher><publisher-name>Centre for Strategic Planning of the Federal Medical and Biological Agency</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47183/mes.2025-327</article-id><article-id custom-type="elpub" pub-id-type="custom">mes-327</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГЛАВНАЯ ТЕМА: ВОПРОСЫ СОВРЕМЕННОЙ ТОКСИКОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MAIN TOPIC: CURRENT ISSUES IN TOXICOLOGY</subject></subj-group></article-categories><title-group><article-title>Противосудорожная активность оригинальных аминоэфиров вальпроевой кислоты при интоксикации ингибитором холинэстераз</article-title><trans-title-group xml:lang="en"><trans-title>Anticonvulsant activity of original valproic acid aminoethers in cholinesterase inhibitor poisoning</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9343-4144</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бельская</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Belskaya</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бельская Алиса Владимировна</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Alisa V. Belskaya</p><p>St. Petersburg</p></bio><email xlink:type="simple">belskayaalisa@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1803-3815</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мелехова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Melekhova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мелехова Александра Сергеевна</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Aleksandra S. Melekhova</p><p>St. Petersburg</p></bio><email xlink:type="simple">melehovaalexandra@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9183-7663</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зорина</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Zorina</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зорина Вероника Николаевна - д-р биол. наук</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Veronika N. Zorina</p><p>St. Petersburg</p></bio><email xlink:type="simple">nilimmun@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8118-8396</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беспалов</surname><given-names>А. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Bespalov</surname><given-names>A. Ya.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Беспалов Александр Яковлевич - канд. хим. наук</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Aleksandr Ya. Bespalov</p><p>St. Petersburg</p></bio><email xlink:type="simple">albesp2011@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2996-5151</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мельникова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Melnikova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мельникова Маргарита Викторовна</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Margarita V. Melnikova</p><p>St. Petersburg</p></bio><email xlink:type="simple">margarita10108@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9754-1537</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бондаренко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bondarenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бондаренко Анастасия Александровна</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Anastasiya A. Bondarenko</p><p>St. Petersburg</p></bio><email xlink:type="simple">bondarenko-nastua@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-клинический центр токсикологии им. академика С.Н. Голикова Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Golikov Scientific and Clinical Center of Toxicology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-клинический центр токсикологии им. академика С.Н. Голикова Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Golikov Scientific and Clinical Center of Toxicology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2025</year></pub-date><volume>27</volume><issue>4</issue><fpage>453</fpage><lpage>461</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бельская А.В., Мелехова А.С., Зорина В.Н., Беспалов А.Я., Мельникова М.В., Бондаренко А.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Бельская А.В., Мелехова А.С., Зорина В.Н., Беспалов А.Я., Мельникова М.В., Бондаренко А.А.</copyright-holder><copyright-holder xml:lang="en">Belskaya A.V., Melekhova A.S., Zorina V.N., Bespalov A.Y., Melnikova M.V., Bondarenko A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.extrememedicine.ru/jour/article/view/327">https://www.extrememedicine.ru/jour/article/view/327</self-uri><abstract><sec><title>Введение</title><p>Введение. Наиболее распространенной причиной острых интоксикаций, сопровождающихся развитием судорожного синдрома, являются ингибиторы холинэстераз в составе бытовой химии, агрохимикатов и ряда лекарственных средств. Отсроченное и повторное применение существующих антидотов малоэффективно. К соединениям, перспективным для разработки альтернативных средств терапии, относятся производные вальпроевой кислоты.</p></sec><sec><title>Цель</title><p>Цель. Оценка противосудорожной эффективности оригинальных аминоэфиров вальпроевой кислоты при интоксикации ингибитором холинэстеразы — фенилкарбаматом.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Эксперименты проведены на беспородных белых крысах-самцах возрастом 3 месяца и массой тела 200– 240 г. При определении средних летальных доз новых соединений использовали табличный экспресс-метод по В.Б. Прозоровскому.</p><p>Для моделирования судорожного синдрома внутрибрюшинно вводили крысам-самцам фенилкарбамат в дозе 1 мг/кг м.т. Оценивали противосудорожную активность аминоэфиров вальпроевой кислоты: N-метил-4-пиперидинольный (АВК), хинуклидинольный (ХАВК) и тропиновый (ТАВК), вводимые в дозах 21,5 и 43 мг/кг м.т. после начала судорог. Исследование проведено на 4 опытных группах: фенилкарбамат «Ф» (n = 8), Ф+АВК (n = 16), Ф+ТАВК (n = 16), Ф+ХАВК (n = 16). Исследуемые субстанции растворяли в 0,9%-ном растворе хлорида натрия и вводили внутрибрюшинно, с учетом межвидового пересчета доз. Объем вводимого внутрибрюшинно раствора составлял 0,1 мл/100 г. Выраженность судорожного синдрома в эксперименте оценивали по шкале Racine. Учитывали показатели эффективности: латентный период, выраженность и продолжительность судорожного синдрома, летальность. Статистическую обработку результатов исследования производили с помощью пакета программы Statistica 13.0 (Statsoft, США).</p></sec><sec><title>Результаты</title><p>Результаты. Установленные значения ЛД50 оригинальных аминоэфиров вальпроевой кислоты соответствуют 3-му классу умеренно токсичных веществ. В дозе 21,5 мг/кг м.т. значимо уменьшалась доля крыс с выраженными судорогами во всех группах, наиболее быстрый противосудорожный эффект регистрировали в группе ХАВК (через 10 мин судороги отсутствовали). Эффективность АВК и ТАВК при использовании в дозе 43 мг/кг м.т. была сопоставима с дозой 21,5 мг/кг м.т., в группе ХАВК через 10 мин доля животных с судорогами оставалась высокой. Достоверное уменьшение продолжительности судорог выявлено в группе ХАВК в дозах 21,5 и 43 мг/кг м.т. Достоверное снижение интенсивности судорог выявлено в группах АВК и ХАВК в дозе 21,5 мг/кг м.т., группах АВК и ТАВК — в дозе 43 мг/кг м.т.</p></sec><sec><title>Выводы</title><p>Выводы. Новые аминоэфиры вальпроевой кислоты проявляют противосудорожную активность при интоксикации обратимым ингибитором холинэстераз. В дозе 21,5 мг/кг м.т. наиболее эффективен ХАВК, однако в дозе 43 мг/кг м.т. наблюдаются проявления токсичности и более эффективен АВК. Несмотря на летальность животных, ТАВК также проявляет свою эффективность в дозе 43 мг/кг м.т.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Cholinesterase inhibitors present in household chemicals, agrochemicals, and a number of medicinal products represent the most common cause of acute intoxications accompanied by the development of convulsive syndrome. Delayed and repeated administration of existing antidotes proves ineffective. Compounds that are promising for the development of alternative therapeutic agents include derivatives of valproic acid.</p></sec><sec><title>Objective</title><p>Objective. Evaluation of the anticonvulsant efficacy of original valproic acid aminoethers in intoxication with phenylcarbamate as a cholinesterase inhibitor.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Experiments were conducted using outbred white male rats aged 3 months with a body weight of 200–240 g. The tabular express method by Prozorovsky was used to determine the median lethal doses of the new compounds. To model the convulsive syndrome, phenylcarbamate was administered intraperitoneally to male rats at a dose of 1 mg/kg bw. The anticonvulsant activity of valproic acid aminoethers — N-methyl-4-piperidinol (VAA), quinuclidinol (QVA), and tropinol (TVA) — was assessed. The preparations were administered at doses of 21.5 mg/kg bw and 43 mg/kg bw after the onset of convulsions. The study was conducted using four experimental groups: phenylcarbamate — P (n = 8), P+VAA (n = 16), P+TVA (n = 16), and P+QVA (n = 16). The test substances were dissolved in 0.9% sodium chloride solution and administered intraperitoneally, taking interspecies dose conversion into account. The volume of the intraperitoneally administered solution was 0.1 mL/100 g. The severity of the convulsive syndrome in the experiment was assessed using the Racine scale. The following efficacy indicators were taken into account: latent period, severity and duration of convulsive syndrome, and mortality. Statistical processing of the research results was performed using the Statistica 13.0 software package (Statsoft, USA).</p></sec><sec><title>Results</title><p>Results. The established LD50 values of the original valproic acid aminoethers under study correspond to class 3 of moderately toxic substances. At a dose of 21.5 mg/kg bw, the proportion of rats with severe convulsions significantly decreased in all groups; the fastest anticonvulsant effect was recorded in the QVA group (after 10 min, convulsions were absent). The efficacy of VAA and TVA at a dose of 43 mg/kg bw was comparable to the dose of 21.5 mg/kg bw; in the QVA group, the proportion of animals with convulsions remained high after 10 min. A significant reduction in the duration of convulsions was revealed in the QVA group at doses of 21.5 mg/kg bw and 43 mg/kg bw. A significant decrease in the intensity of convulsions was detected in the VAA and QVA groups at a dose of 21.5 mg/kg bw, and at a dose of 43 mg/kg bw in the VAA and TVA groups.</p></sec><sec><title>Conclusions</title><p>Conclusions. The new aminoethers of valproic acid exhibit anticonvulsant activity in intoxication with a reversible cholinesterase inhibitor. At a dose of 21.5 mg/kg bw, QVA is the most effective; however, at a dose of 43 mg/kg bw, manifestations of toxicity are observed and VAA is more effective. Despite animal mortality, TVA also demonstrates its efficacy at a dose of 43 mg/kg bw.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>аминоэфиры вальпроевой кислоты</kwd><kwd>судорожный синдром</kwd><kwd>ингибиторы холинэстераз</kwd><kwd>карбаматы</kwd><kwd>противосудорожная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>valproic acid aminoethers</kwd><kwd>convulsive syndrome</kwd><kwd>cholinesterase inhibitors</kwd><kwd>carbamates</kwd><kwd>anticonvulsant therapy</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Верведе А.Б. за помощь в статистической обработке данных, Прокопенко Л.И. за синтез оригинальных аминоэфиров вальпроевой кислоты</funding-statement><funding-statement xml:lang="en">the authors express their gratitude to Alexey B. Verveda for his assistance in statistical data processing and to Ljubov I. Prokopenko for the synthesis of the original valproic acid aminoethers</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">King AM, Aaron CK. Organophosphate and carbamate poisoning. Emergency Medicine Clinics of North America. 2015;33(1):133–51. https://doi.org/10.1016/j.emc.2014.09.010</mixed-citation><mixed-citation xml:lang="en">King AM, Aaron CK. Organophosphate and carbamate poisoning. Emergency Medicine Clinics of North America. 2015;33(1):133–51. https://doi.org/10.1016/j.emc.2014.09.010</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Matošević A, Bosak A. Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents. Arhiv za Higijenu Rada I Toksikologiju. 2020;71(4):285–99. https://doi.org/10.2478/aiht-2020-71-3466</mixed-citation><mixed-citation xml:lang="en">Matošević A, Bosak A. Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents. Arhiv za Higijenu Rada I Toksikologiju. 2020;71(4):285–99. https://doi.org/10.2478/aiht-2020-71-3466</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy BS, Skaria TG, Polepalli S, Vidyasagar S, Rao M, Vijayanarayana K, et al. Factors associated with outcomes in organophosphate and carbamate poisoning: a retrospective study. Toxicological Research. 2020;36(3):257–66. https://doi.org/10.1007/s43188-019-00029-x</mixed-citation><mixed-citation xml:lang="en">Reddy BS, Skaria TG, Polepalli S, Vidyasagar S, Rao M, Vijayanarayana K, et al. Factors associated with outcomes in organophosphate and carbamate poisoning: a retrospective study. Toxicological Research. 2020;36(3):257–66. https://doi.org/10.1007/s43188-019-00029-x</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Гладких ВД, Назаров ВБ. Реактиваторы холинэстеразы в терапии отравлений нейротропными физиологически активными веществами. Медицина экстремальных ситуаций. 2014;1(47):54–6. EDN: SAFQEV</mixed-citation><mixed-citation xml:lang="en">Gladkih VD, Nazarov VB. Cholinesterase reactivators in the therapy of intoxication with neurotropic physiologically active substances. Extreme Medicine. 2014;1(47):54–6 (In Russ.). EDN: SAFQEV</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Alozi M, Rawas-Qalaji M. Treating organophosphates poisoning: management challenges and potential solutions. Critical Reviews in Toxicology. 2020;50(9):764–79. https://doi.org/10.1080/10408444.2020.1837069</mixed-citation><mixed-citation xml:lang="en">Alozi M, Rawas-Qalaji M. Treating organophosphates poisoning: management challenges and potential solutions. Critical Reviews in Toxicology. 2020;50(9):764–79. https://doi.org/10.1080/10408444.2020.1837069</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy DS. Mechanism-based novel antidotes for organophosphate neurotoxicity. Current Opinion in Toxicology.2019;14:35–45. https://doi.org/10.1016/j.cotox.2019.08.001</mixed-citation><mixed-citation xml:lang="en">Reddy DS. Mechanism-based novel antidotes for organophosphate neurotoxicity. Current Opinion in Toxicology.2019;14:35–45. https://doi.org/10.1016/j.cotox.2019.08.001</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Romoli M, Mazzocchetti P, D’Alonzo R, Siliquini S, Rinaldi VE, Verotti A, et al. Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. Current Neuropharmacology. 2019;17(10):926–46 https://doi.org/10.2174/1570159X17666181227165722</mixed-citation><mixed-citation xml:lang="en">Romoli M, Mazzocchetti P, D’Alonzo R, Siliquini S, Rinaldi VE, Verotti A, et al. Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. Current Neuropharmacology. 2019;17(10):926–46 https://doi.org/10.2174/1570159X17666181227165722</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bialer M, Cross H, Hedrich UBS, Lagae L, Lerche H, Loddenkemper T. Novel treatment approaches and pediatric research networks in status epilepticus. Epilepsy &amp; Behavior. 2019;101(Pt B):106564. https://doi.org/10.1016/j.yebeh.2019.106564</mixed-citation><mixed-citation xml:lang="en">Bialer M, Cross H, Hedrich UBS, Lagae L, Lerche H, Loddenkemper T. Novel treatment approaches and pediatric research networks in status epilepticus. Epilepsy &amp; Behavior. 2019;101(Pt B):106564. https://doi.org/10.1016/j.yebeh.2019.106564</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Delage C, Palayer M, Etain B, Hagenimana M, Blaise N, Smati J, et al. Valproate, divalproex, valpromide: Are the differences in indications justified? Biomedicine &amp; Pharmacotherapy. 2023;158:114051. https://doi.org/10.1016/j.biopha.2022.114051</mixed-citation><mixed-citation xml:lang="en">Delage C, Palayer M, Etain B, Hagenimana M, Blaise N, Smati J, et al. Valproate, divalproex, valpromide: Are the differences in indications justified? Biomedicine &amp; Pharmacotherapy. 2023;158:114051. https://doi.org/10.1016/j.biopha.2022.114051</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mawasi H, Bibi D, Shekh-Ahmad T, Shaul C, Blotnik S, Bialer M. Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. Molecular Pharmaceutics. 2016;13(7):2492–6. https://doi.org/10.1021/acs.molpharmaceut.6b00221</mixed-citation><mixed-citation xml:lang="en">Mawasi H, Bibi D, Shekh-Ahmad T, Shaul C, Blotnik S, Bialer M. Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. Molecular Pharmaceutics. 2016;13(7):2492–6. https://doi.org/10.1021/acs.molpharmaceut.6b00221</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Haines KM, Matson LM, Dunn EN, Ardinger CE, LeeStubbs R, Bibi D, et al. Comparative efficacy of valnoctamide and sec-butylpropylacetamide (SPD) in terminating nerve agent-induced seizures in pediatric rats. Epilepsia. 2019;60(2):315–21 https://doi.org/10.1111/epi.14630</mixed-citation><mixed-citation xml:lang="en">Haines KM, Matson LM, Dunn EN, Ardinger CE, LeeStubbs R, Bibi D, et al. Comparative efficacy of valnoctamide and sec-butylpropylacetamide (SPD) in terminating nerve agent-induced seizures in pediatric rats. Epilepsia. 2019;60(2):315–21 https://doi.org/10.1111/epi.14630</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Прозоровский ВБ. Статистическая обработка результатов фармакологических исследований. Психофармакология и биологическая наркология. 2007;7(3–4):2090–120.</mixed-citation><mixed-citation xml:lang="en">Prozorovsky VB. Statistical processing of pharmacological research results. Psychopharmacology &amp; Biological Narcology. 2007;7(3–4):2090–120 (In Russ.). EDN: JVWCBJ</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Прокопенко ЛИ, Зайцева МА, Беспалов АЯ, Мелехова АС, Петров АН, Бельская АВ и др. Гидрохлорид (1-метилпиперидин-4-ил)-2-пропилпентаноат, обладающий холинолитической и противосудорожной активностью. Патент Российской. Федерации № 2714135; 2020.</mixed-citation><mixed-citation xml:lang="en">Prokopenko LI, Zaitseva MA, Bespalov AYa, Melekhova AS, Petrov AN, Belskaya AV, et al. Hydrochloride (1-methylpiperidin-4-yl)-2-propylpentanoate, which has anticholinergic and anticonvulsant activity. Patent of the Russian Federation No. 2714135; 2020 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Беспалов АЯ, Прокопенко ЛИ, Горчакова ТЛ, Козлов ВК, Петров АН, Зайцева МА и др. Гидрохлориды замещенных 2-[(диметиламино)метил] арилдиметилкарбоматов, обладающие антихолинэстеразной активностью. Патент Российской. Федерации № 2754133; 2021.</mixed-citation><mixed-citation xml:lang="en">Bespalov AYа, Prokopenko LI, Gorchakova TL, Kozlov VK, Petrov AN, Zaitseva MA, et al. Hydrochlorides of substituted 2-[(dimethylamino)methyl] aryldimethyl carbomates with anticholinesterase activity. Patent of the Russian Federation. No. 2754133; 2021 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Мелехова АС, Бельская АВ, Зорина ВН, Мельникова МВ, Кубарская ЛГ, Гайкова ОН. Новая экспериментальная модель судорожного синдрома на основе фенилкарбамата.</mixed-citation><mixed-citation xml:lang="en">Melekhova AS, Belskaya AV, Zorina VN, Melnikova MG, Kubarskaya LG, Gaikova ON. Experimental model of convulsive syndrome based on phenylcarbamate. Extreme Medicine. 2024;26(4):38–48 (In Russ.). https://doi.org/10.47183/mes.2024-26-4-38-48</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Racine RJ Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalography and Clinical Neurophysiology. 1972;32(3):281–94. https://doi.org/10.1016/0013-4694(72)90177-0</mixed-citation><mixed-citation xml:lang="en">Racine RJ Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalography and Clinical Neurophysiology. 1972;32(3):281–94. https://doi.org/10.1016/0013-4694(72)90177-0</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Мелехова АС, Петров АН, Беспалов АЯ, Бельская АВ, Мельникова МВ, Зацепин ЭП и др. Экспериментальная фармакотерапия судорожного синдрома при моделировании тяжелого отравления карбаматом. Medline.ru. Российский биомедицинский журнал. 2019;20(2):294–306.</mixed-citation><mixed-citation xml:lang="en">Melekhova AS, Petrov AN, Bespalov AY, Belskaya AV, Melnikova MV, Zatsepin EP, et al. Experimental pharmacotherapy of convulsive syndrome in the simulation of severe carbamate poisoning. Medline.ru. Russian Biomedical Journal 2019;20(2):294–306 (In Russ.). EDN: JRVAPQ</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
